| Topic | Key details | Evidence (citation id) | Publication (year; journal) | URL |
|---|---|---|---|---|
| Definition/classification | GM1 gangliosidosis type III is the adult/chronic, least severe form of GM1 gangliosidosis, a lysosomal storage disorder due to β-galactosidase deficiency; the phenotype spectrum is divided into infantile (type I), late-infantile/juvenile (type II), and adult/chronic (type III). | (pqac-00000002, pqac-00000003, pqac-00000012) | 2024; Genetics in Medicine; 2021; chapter source; 2026; Journal of Inherited Metabolic Disease | https://doi.org/10.1016/j.gim.2024.101144 |
| Identifiers | ICD-10: E75.1 for GM1 gangliosidosis; OMIM/MIM: 230650 for type III adult form; related subtype OMIMs: 230500 (type I infantile) and 230600 (type II late-infantile/juvenile). MeSH mapping available for GM1 gangliosidosis: D016537. | (pqac-00000034, pqac-00000035, pqac-00000036, pqac-00000038) | 2024; Frontiers in Genetics; 2025; Scientific Reports; 2024; Genetics in Medicine; 2020; ClinicalTrials.gov registry | https://doi.org/10.3389/fgene.2024.1344051 |
| Inheritance/causal gene | Autosomal recessive disease caused by biallelic pathogenic variants in GLB1 (chromosome 3p21.33), encoding lysosomal β-galactosidase required for degradation of GM1 ganglioside and related glycoconjugates. | (pqac-00000004, pqac-00000008) | 2026; Tremor and Other Hyperkinetic Movements; 2024; Genetics in Medicine | https://doi.org/10.5334/tohm.1152 |
| Typical onset | Adult/chronic type III is classically described as beginning in the 2nd–3rd decade, but published ranges extend from about 3–30 years; one recent series reported median onset at 6 years (range 3–18), illustrating marked heterogeneity. | (pqac-00000002, pqac-00000005, pqac-00000009) | 2024; Genetics in Medicine; 2025; Frontiers in Pediatrics; 2026; Tremor and Other Hyperkinetic Movements | https://doi.org/10.1016/j.gim.2024.101144 |
| Residual enzyme activity | Type III patients typically retain approximately 5–10% residual β-galactosidase activity; severity across GM1 correlates inversely with residual enzyme activity. | (pqac-00000004, pqac-00000006) | 2026; Tremor and Other Hyperkinetic Movements; 2021; chapter source | https://doi.org/10.5334/tohm.1152 |
| Hallmark clinical features | Progressive movement-disorder phenotype dominated by generalized dystonia, often with prominent oromandibular/lingual/cranio-cervical involvement; dysarthria is frequent/universal in reported series; corticospinal signs are common. Adult/chronic disease may also show vertebral abnormalities, while skeletal findings can be subtle overall. | (pqac-00000009, pqac-00000010, pqac-00000013, pqac-00000012) | 2026; Tremor and Other Hyperkinetic Movements; 2026; Tremor and Other Hyperkinetic Movements; 2021; chapter source; 2026; Journal of Inherited Metabolic Disease | https://doi.org/10.5334/tohm.1152 |
| Imaging | Reported neuroimaging signature in type III includes bilateral posterior putaminal T2/FLAIR abnormalities and a pallidal susceptibility-weighted imaging (SWI) “wishbone” sign; broader GM1 imaging features include basal ganglia/thalamic signal changes and progressive white-matter/cerebellar/cortical involvement. | (pqac-00000009, pqac-00000012, pqac-00000023) | 2026; Tremor and Other Hyperkinetic Movements; 2026; Journal of Inherited Metabolic Disease; 2026; Journal of Inherited Metabolic Disease | https://doi.org/10.5334/tohm.1152 |
| Heterogeneity and prognosis | Type III is the mildest, slowest-progressing GM1 phenotype and is the form in which survival into adulthood is typical. Clinical expression is heterogeneous, with variable cognitive involvement and overlap with Morquio B/skeletal-predominant GLB1 disease depending on variant location/effect. | (pqac-00000001, pqac-00000004, pqac-00000012) | 2026; Journal of Inherited Metabolic Disease; 2026; Tremor and Other Hyperkinetic Movements; 2026; Journal of Inherited Metabolic Disease | https://doi.org/10.1002/jimd.70134 |


*Table: This table summarizes core disease-definition, genetics, phenotype, imaging, and identifier facts for GM1 gangliosidosis type III. It is useful as a compact reference for a disease knowledge base entry and highlights both canonical adult-onset descriptions and the marked clinical heterogeneity reported in recent literature.*